Placebo News and Research

RSS

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Coffee consumption not related to alertness

The stimulatory effects of caffeine may be nothing more than an illusion according to new research, which shows there is no real benefit to be gained from the habitual morning cup of coffee.

4 Jun 2010

Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

4 Jun 2010

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.

4 Jun 2010

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS). The trial, referred to as ASMP3001, is the first of two Phase 3 trials being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for U.S. registration. This first trial will be conducted at 120 sites in the U.S.

4 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Combined alcohol dependency treatments reduce social costs of health care: Study

Combining medications and behavioral interventions for treating alcohol-dependent patients reduces social costs of health care, arrests and motor vehicle accidents, according to a new study by researchers at RTI International, University of Wisconsin-Milwaukee, University of North Carolina at Chapel Hill, University of Pennsylvania and Yale University.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

3 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Geisinger Medical Center will participate in ProTECT III, a groundbreaking National Institute of Health -sponsored research study for the emergency treatment of traumatic brain injuries using the hormone progesterone.

2 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

Placebo News and Research

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Coffee consumption not related to alertness

Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Combined alcohol dependency treatments reduce social costs of health care: Study

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News